Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

SYK

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

SYK

AI Research Report

Powered by Claude

Ready to analyze SYK

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Healthcare →
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
JNJ
Johnson & Johnson
—
—
TMO
Thermo Fisher
—
—
WELL
Welltower
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings in 16d (Apr 30)
Stryker Corp

Stryker Corp

Health Care·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1980-03-17
  • Yahoo·5h ago

    Telix Expands Board As Valuation And Momentum Draw Investor Attention

    Telix Pharmaceuticals (ASX:TLX) has expanded its Board with the appointment of Dr. Maria Rivas and William Jellison as non executive directors. Dr. Rivas brings senior experience from Pfizer and prior public company board roles. Jellison adds corporate finance expertise from his tenure as CFO at Stryker Corporation. These changes follow the recent addition of David Gill, who is expected to become Chair, as part of a broader succession and governance plan. For readers tracking ASX:TLX, the...

  • Yahoo·8h ago

    Stryker's Q1 Results to See Material Impact From March Cybersecurity Incident, RBC Says

    Stryker (SYK) is expected to see a financial impact to its Q1 results, when the company reports its

  • Yahoo·8h ago

    Stryker to Acquire AVS, Adding IVL Capabilities to Vascular Portfolio

    SYK to acquire Amplitude Vascular Systems, adding next-gen IVL tech to boost its peripheral vascular portfolio and expand arterial disease treatment reach.

  • Benzinga·15h ago

    BTIG Reiterates Buy on Stryker, Maintains $397 Price Target

    BTIG analyst Ryan Zimmerman reiterates Stryker (NYSE:SYK) with a Buy and maintains $397 price target.

  • Fintel·23h ago

    Leerink Partners Initiates Coverage of Stryker (SYK) with Outperform Recommendation

  • Yahoo·1d ago

    Stryker agrees to acquire IVL developer Amplitude Vascular Systems

    Amplitude Vascular’s lead development product is an intravascular lithotripsy platform for calcified peripheral artery disease treatment.

  • Yahoo·3/9/2026

    Netflix resumed, Starbucks downgraded: Wall Street's top analyst calls

    Netflix resumed, Starbucks downgraded: Wall Street's top analyst calls

  • Finnhub·1d ago

    Stryker Corporation signed a definitive agreement Amplitude Vascular Systems, Inc.

    Stryker Corporation signed a definitive agreement Amplitude Vascular Systems, Inc. on April 13, 2026. The deal remains subject to customary closing conditions....

  • View all news →
NEW YORK STOCK EXCHANGE, INC.After-hours
Stryker Corp
Health Care
—
— (—)
Open
—
Prev close
—
Day range
— – —
52W range
$319.32 – $404.87
Mkt cap
$132.88B
P/E
41.2
EPS
$8.40
Beta
0.92

Fundamentals

Valuation
Market Cap
$132.88B
P/E (TTM)
41.18S&P avg ~22
P/S (TTM)
5.32S&P avg ~2.8
P/B
6.00S&P avg ~4.5
P/FCF
31.21S&P avg ~26
EPS (TTM)
$8.40
Book/sh
$58.61
Cash/sh
$10.72
Profitability
Gross Margin
64.57%avg ~45%
Operating Margin
19.43%avg ~15%
Net Margin
12.92%avg ~12%
ROE
15.04%avg ~18%
ROA
6.93%avg ~7%
ROI
8.63%
Payout Ratio
39.56%
FCF/sh
—
Growth & Health
Rev Growth YoY
11.16%
Rev Growth 5Y
11.84%
EPS Growth YoY
8.18%
EPS Growth 5Y
14.84%
Current Ratio
—
Quick Ratio
1.04
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.92
52W High
$404.87
52W Low
$319.32
Avg Vol (10D)
1.79M
Avg Vol (3M)
1.96M
Div Yield
1.01%
Div/sh (TTM)
—
Analyst
Buy (36)
Price Performance
5D+4.57%
MTD+5.68%
3M-5.44%
6M-5.20%
YTD-1.20%
1Y-0.33%

Factor Grades

View details →
C+
Overall score: 54/100
C-
Valuation
B-
Growth
B-
Profitability
D
Momentum
B
Financial Health

Recent insider activity

View all →
  • 4FORM 4
    21d ago
  • 4FORM 4
    21d ago
  • 4FORM 4
    21d ago
  • 4FORM 4
    21d ago
  • 4FORM 4
    21d ago